Cambridge Healthtech Institute’s Third Annual
High-Concentration Protein Formulations
Overcoming Challenges in High Viscosity, Aggregation and Stability
Part of CHI’s 6th Annual The Bioprocessing Summit
August 20-21, 2014 | Renaissance Waterfront Hotel | Boston, Massachusetts
At higher concentrations, proteins or antibodies exhibit characteristic problems including aggregation, precipitation, gelation, and increased viscosity. Development of these high protein concentration formulations results in several manufacturing, stability, analytical, and delivery challenges. Thus, development of formulations for protein drugs requiring high dosing requires specific strategies. This popular annual conference will feature informative, high-quality case studies and successful strategies to overcome the problems you are facing in the rapidly changing biotherapeutic landscape.
We invite you to submit a proposal to speak, especially unpublished and innovative work on the development of high-concentration protein formulations, present a poster, or to attend to learn from and network with the leading experts from around the world.
- Mechanisms of Protein Association and Aggregation
Thomas Laue, Ph.D., Professor, Biochemistry and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire
- Liquid-Liquid Phase Separation as a Quantitative Colloidal Stability Assay for Monoclonal Antibodies
Ramil F. Latypov, Ph.D., Principal Scientist, Process & Product Development, Amgen, Inc.
Multimer Protein Cluster Structure at High Concentration: Dynamic Modeling of Stability and Viscosity
John Tsavalas, Ph.D., Assistant Professor of Materials Science, University of New Hampshire
Understanding and Addressing Viscosity in the Development of High-Concentration Protein Formulations
Robert H. Walters, Senior Scientist, Biotherapeutics Pharmaceutical R&D, Pfizer, Inc.
Monoclonal Antibody Self-Association, Rheology, and Phase Behavior at High Concentrations
Wenhua Wang, Ph.D., Postdoctoral Fellow, Late Stage Pharmaceutical Development, Genentech, Inc.
Challenges in Developing High-Concentration Liquid Formulations for Novel Biologics Formats: Fusion Protein, Bi-Specifics
Kapil Gupta, Ph.D., Senior Fellow, Integrated Biologics Profiling, Novartis Institute of Biomedical Research
Orthogonal Toolbox for Screening and Identification of High-Concentration mAb Formulations
Yunsong “Frank” Li, Ph.D., Associate Principal Scientist, Bioprocess Development, Merck Research Laboratories
Overcoming Formulation Challenges for Subcutaneous Drug Delivery of High-Concentration/Dose Formulation
Michael LaBarre, Ph.D., Vice President, Product Development, Halozyme Therapeutics
Challenges in Reconstitution of High-Concentration Protein Formulations
Pooja Sane, Doctoral Candidate, Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut
Co-Developed by: Robin Bogner, Ph.D., Associate Professor, Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut